GEN-MKT-18-7897-A
Feb 18, 2026 | Biopharma, Blogs, Pharma | 0 comments
Read time: 3 minutes
For decades, SCIEX has been part of bioanalytical innovation, empowering scientists in pharma and biopharma to push the boundaries of sensitivity, accuracy, and throughput. Across complex workflows and increasingly challenging therapeutic modalities.
Today, we’re spotlighting three peer‑reviewed publications, spanning nearly thirty years, that reflect how the scientific community continues to innovate. From oligonucleotide quantitation to protein bioanalysis, these studies highlight the evolution in the field and the long-term partnerships we value.
Publication: 🔗 https://pubs.acs.org/doi/full/10.1021/ac0618674
The study showcased how thoughtful chromatographic design, structured optimization, and careful attention to matrix effects could deliver reliable quantitation even in challenging biological samples. Many of the best practices introduced here, including instrument stability, ionization efficiency, and systematic validation, still underpin quantitative workflows today.
Abstract
Electrospray ionization (ESI) liquid chromatography−tandem mass spectrometry (LC/MS/MS) assays provide high-throughput and selective methods for quantitation of small molecules. Use of LC/MS/MS assays for macromolecules, like oligonucleotides, is challenging due to lack of sensitivity and low analyte recovery from biomatrixes. Due to this fact, the method of choice for oligonucleotides quantitation remains hybridization-based ligand-binding assays…
Publication: 🔗 https://pubs.acs.org/doi/full/10.1021/ac501837t
This publication introduced an innovative, cost-effective approach for protein depletion using combinations of organic solvents and acids, validated through signature peptide monitoring. The result? Cleaner extracts, improved sensitivity, and greater confidence in LC–MS/MS quantitation of therapeutic proteins.
We have developed an innovative method to remove albumin from plasma/serum samples for the LC-MS/MS quantitation of therapeutic proteins. Different combinations of organic solvents and acids were screened for their ability to remove albumin from plasma and serum samples. Removal efficiency was monitored by two signature peptides (QTALVELVK and LVNEVTEFAK) from albumin …
Publication: 🔗 https://www.tandfonline.com/doi/full/10.1080/…
This 2024 publication captures the cutting edge: hybridization‑based LC–MS/MS approach to measure trace levels of free antisense oligonucleotide payload in complex biological matrices. It demonstrates how advanced workflows, combining sample prep with sensitive mass spectrometry, are enabling scientists to tackle the challenges of next‑generation modalities.
We have developed an innovative method to remove albumin from plasma/serum samples for the LC-MS/MS quantitation of therapeutic proteins. Different combinations of organic solvents and acids were screened for their ability to remove albumin from plasma and serum samples. Removal efficiency was monitored by two signature peptides (QTALVELVK and LVNEVTEFAK) from albumin. Isopropanol with 1.0% trichloroacetic acid was found to be the most effective combination to remove albumin while retaining the protein of interest. Our approach was compared with a commercial albumin depletion kit on both efficiency of albumin removal and recovery of target proteins…
Each decade has brought new questions and new scientific ingenuity to the forefront. And through it all, SCIEX solutions and partnerships have helped researchers stay ahead of the curve.
As therapeutic innovation accelerates, bioanalysis will continue to evolve. Modalities will diversify. Performance expectations will rise. Workflows will become more hybrid, more integrated, and more data‑driven. SCIEX is committed to supporting scientists on that journey with tools designed not just for today’s challenges, but for tomorrow’s discoveries.
Ready to advance your bioanalysis workflows further?
Explore SCIEX Bioanalysis & DMPK Applications pages >
Discover solutions, workflows, and technical insights designed to help you push sensitivity, accelerate method development, and solve complex quantitation challenges.
Join the BioA Collective on LinkedIn >
Connect with a global community of bioanalytical scientists, share expertise, and stay inspired by real‑world innovation.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network